Silexion Therapeutics
Development of Innovative Treatments for Pancreatic Cancer
StartupSilexion Therapeutics is a Modi'in-Maccabim-Re'ut-based startup in the Health Tech & Life Sciences sector, established in 2008. Development of Innovative Treatments for Pancreatic Cancer. The company has raised a total of $27.65M across 6 funding rounds, currently at the Public stage. Silexion Therapeutics was founded by Amotz Shemi, PhD. Key investors include Esperante Ventures. The company has 11-50 employees. Core technologies: Biologicals, Genes.
With $27.65M in total funding, Silexion Therapeutics is a Public-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StagePublic
- ProductClinical Trial
- ModelB2B
- Employees11-50
- HQModi'in-Maccabim-Re'ut
- DistrictCenter District
- Last Round$6M
- Esperante VenturesLead
Amotz Shemi, PhDCo-Founder & CEO
51 articles covered by sources including finance.yahoo.com,
www.globenewswire.com,
www.businesswire.com,
www.calcalistech.com,
nocamels.com.
What does Silexion Therapeutics do?
Silexion Therapeutics is a pioneering developmental stage company dedicated to the development of innovative treatments for pancreatic cancer. The company conducted phase 2 clinical trial with its first generation product which has shown positive efficacy results vs the control of chemotherapy alone. Silexion’s commitment to pushing the boundaries of therapeutic advancements in the field of oncology, is focused in enhancing its first-generation product (LODERTM) to develop a new formulated product which will improve the clinical efficacy that Silexion observed with its first-generation product against pancreatic cancer. With a strong foundation in RNA interference technology, Silexion Therapeutics develops innovative RNA-based therapeutics designed to silence specific genes involved in pancreatic cancer growth and metastasis. By selectively suppressing these genes, it aims to disrupt tumor progression and enhance the therapeutic response.
How much funding has Silexion Therapeutics raised?
Silexion Therapeutics has raised $27.65M in total funding across 6 rounds. The company is currently at the Public stage. Key investors include Esperante Ventures.
Who founded Silexion Therapeutics?
Silexion Therapeutics was founded in 2008 by Amotz Shemi, PhD (Co-Founder & CEO).
What sector is Silexion Therapeutics in?
Silexion Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Genes. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is Silexion Therapeutics located?
Silexion Therapeutics is based in HaMa'ayan Street 2, Modi'in-Maccabim-Re'ut, Israel, Center District.